Teriparatide vs Abaloparatide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicTeriparatideAbaloparatide
What it is

Parathyroid hormone (1-34). The label states that teriparatide binds the same receptors as natural parathyroid hormone, with the same effects on bone and kidney.1

A PTHrP(1-34) analogue that the label says acts on the PTH1 receptor and stimulates new bone formation.7

FDA status

FDA-approved

FDA-approved as Forteo and other teriparatide products1,2,3,4,5,6

FDA-approved. Drugs@FDA lists Forteo with an original approval date of November 26, 2002, and later teriparatide applications, the most recent approved on October 23, 2026. The cited label has no boxed warning.1,2,3,4,5,6

Is teriparatide FDA-approved?

FDA-approved

FDA-approved as Tymlos for osteoporosis7,8

FDA-approved. Drugs@FDA lists Tymlos with an original approval date of April 28, 2017. The cited label has no boxed warning; its warnings include a risk of osteosarcoma seen in rats.7,8

Is abaloparatide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.9

Not among the six peptides the policy lists.9

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Controlled human trial A double-blind, placebo-controlled trial in 1,637 postmenopausal women with osteoporosis, with new spine fractures as the main outcome and a median exposure of 19 months.1
  • Controlled human trial A double-blind, placebo-controlled trial in 437 men with primary or hypogonadal osteoporosis that measured spine bone density.1
  • Large randomized human trial An 18-month randomized, double-blind, active-controlled trial in 428 people with osteoporosis linked to glucocorticoid use.1

Large randomized human trials

  • Large randomized human trial Study 003 (NCT01343004): an 18-month randomized, double-blind, placebo-controlled trial in 1,645 participants, postmenopausal women aged 49 to 86 with osteoporosis, with new spine fractures as the main outcome.7
  • Controlled human trial Study 019 (NCT03512262): a 12-month randomized, double-blind, placebo-controlled trial in 228 men with osteoporosis that measured bone density.7
Records collected

73 ClinicalTrials.gov records and 62 PubMed records collected

9 ClinicalTrials.gov records and 33 PubMed records collected

Area of study

Bone and growth1

Bone and growth7

Latest dated events
  1. FDA approves another generic teriparatide application (ANDA214412), according to Drugs@FDA.6
  2. DailyMed publishes the teriparatide label version cited on this page, which adds a separate warning about allergic reactions.1
  3. FDA approves a generic teriparatide application, according to Drugs@FDA.4
  1. DailyMed publishes the Tymlos label version cited on this page.7
  2. FDA approves Tymlos, according to Drugs@FDA.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Teriparatide injection, solution · SPL version 10 · published 2026-09-21 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA application NDA021318 · original submission status AP · 2002-11-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA211939 · original submission status AP · 2019-10-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application ANDA211097 · original submission status AP · 2023-11-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA218771 · original submission status AP · 2024-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application ANDA214412 · original submission status AP · 2026-10-23 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026

  7. 7
    TYMLOS (abaloparatide) injection, solution · SPL version 19 · published 2026-08-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  8. 8
    Drugs@FDA application NDA208743 · original submission status AP · 2017-04-28 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026